What's even more impressive is that much of this growth was organic, although AstraZeneca's $39bn acquisition of rare disease specialist Alexion added $3bn of new revenues in 2021, while sales of COVID vaccine Vaxzevria came in at $3.9bn, having earned just a couple of million dollars in 2020. By my count, the company earned blockbuster (>$1bn per annum) sales from no fewer than 13 drug products in 2021, as total revenues increased by an impressive 38% year-on-year. That compares favorably with most of the "Big 8" US pharmas, Johnson & Johnson ( JNJ), Eli Lilly ( LLY), Pfizer ( PFE), AbbVie ( ABBV), Merck ( MRK), Bristol Myers Squibb ( BMY), Amgen ( AMGN) and Gilead Sciences ( GILD) - of these, only Eli Lilly, +288%, and AbbVie, +98%, have performed better.ĪstraZeneca earned $37.8bn of revenues in FY21, which is more than Amgen, Gilead, and Eli Lilly, but lower than the remaining "Big 8" US pharmas, and its dividend yield of 2.2% ($2.9 per annum) is lower than all but Eli Lilly. Over a five-year period, AstraZeneca stock is up more than 90%, providing an attractive return for investors. I gave the company a buy recommendation and shares have risen in value by 11% since then, trading at a price of $65, resulting in a market cap valuation of almost exactly $200bn. It has been over a year since my last post for Seeking Alpha on AstraZeneca ( NASDAQ: AZN), the Anglo / Swedish Pharmaceutical giant. Megaflopp/iStock via Getty Images Investment Thesis
0 kommentar(er)
